Use of viral cis-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
CA 2248539 A1 · Owner: The Immune Response Corporation · Inventors: Ill, Charles R.; Bidlingmaier, Scott
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Expression vectors are disclosed comprising intronless genes containing one or more near consensus splice sequences and one or more copies of a viral cisacting post-transcriptional regulatory element which is transcribed along with the gene and causes export of the gene transcript from the nucleus into the cytoplasm of the cell. In a preferred embodiment the vectors are targeted for , delivery to specific cells in the form of a molecular complex made up of the plasmid releasably linked to a nucleic acid binding agent and a ligand which binds to a component on the surface of a cell. Use of viral cis-acting posttranscriptional regulatory elements as disclosed can increase expression of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 10, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 10, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 10, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.